In this photo is a Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March 28, 2024. (Photographer: Shelby Knowles/Bloomberg) The anti-obesity drug Zepbound ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

Zepbound is the newest GLP-1 medication to be approved by the Food and Drug Administration (FDA) for weight loss. It’s available only by prescription for people with a body mass index (BMI) of ...

The new vials – priced at $399 and $549, respectively, for a month's supply – are a lower-cost alternative to the current injector pen formulation of Zepbound and are easier to produce.

Before injecting Zepbound, make sure to check the liquid in the vial or pen. The solution should look clear and colorless to slightly yellow. Do not use the medication if you see any particles or ...

Eli Lilly and other drugmakers are reportedly planning to urge the Trump administration to pause Medicare drug-price ...

"Ozempic is the only version among the weekly injectables — Ozempic, Wegovy, Zepbound and Mounjaro — that has the option to ‘hack’ the pen for a smaller dose," Dr. Alexandra Sowa ...

Following positive results from its SURMOUNT-5 trial, Eli Lilly’s Zepbound (tirzepatide) will surpass Novo Nordisk’s Weogvy (semaglutide) in the obesity treatment market, according to a ...

Why it matters: Lilly's growth prospects are driven by Mounjaro and Zepbound, and shortfalls in sales could portend weaker long-term potential for this market. Lilly is positioned to remain the ...